News & References

Below is a curated collection of recent literature and resources relevant to the national effort to address HCV and complex comorbidities within primary care.

Check back often as we are regularly updating these resources.

Publications from our program

  • Significant increase in risk of fibrosis or cirrhosis at time of HCV diagnosis for Hispanics with diabetes and obesity compared with other ethnic groups. Clin Gastroenterol Hepatol. 2019;17(7).
  • Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis. Hepatology. 2019; 70(1).
  • Cost-Effectiveness of Hepatitis C Screening and Treatment in Low-Income, Primarily Hispanic Baby Boomers. J Health Care Poor Underserved. 2019;30(3)
  • The Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South Texas. J Oncol Pract. 2019; 15(2).

Clinical infrastructure

  • Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis. Hepatology. 2019; 70(1).
  • Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis. Clin Gastroenterol Hepatol. 2019;17(9).
  • The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Clin Gastroenterol Hepatol. 2019;17(9).
  • The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Hepatology. (2019)

Serving vulnerable or underserved populations

  • Dietary patterns and risk of hepatocellular carcinoma among US men and women. Hepatology. 2019; 70(2).
  • Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. Digestive Diseases and Sciences. Dig Dis Sci. 2018 Dec;63(12).

Treatment access and considerations

  • Indelibly stamped by hepatitis C virus infection: persistent epigenetic signatures increasing liver cancer risk. Gastroenterology. 2019;156(8).
  • Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C. Digestive Diseases and Sciences. Dig Dis Sci. 2018 Dec;63(12).
  • Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med. 2017; 376(22)
  • Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017; 68
  • Hepatitis C in chronic kidney disease – an overview of the KDIGO guideline. Clin Gastroenterol Hepatol. 2019 Jul 31.
  • Patients with signs of advanced liver disease and clinically significant portal hypertension do not necessarily have cirrhosis. Clin Gastroenterol Hepatol. 2019;17(10)
  • Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality. Clin Gastroenterol Hepatol. 2019; 17(10)

Funding issues

  • Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. Virus Res. 2018; 248